Lexeo Therapeutics' CEO R. Nolan Townsend discusses a recent acquisition in Friedreich's ataxia and upcoming data in PKP2 arrhythmogenic cardiomyopathy
He describes how the company has transformed from being a gene therapy company focused on cardiology to having a broader approach to treating the root of disease.









.png)